Your browser doesn't support javascript.
loading
A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability
Xiangyang Chi; Renhong Yan; Jun Zhang; Guanying Zhang; Yuanyuan Zhang; Meng Hao; Zhe Zhang; Pengfei Fan; Yunzhu Dong; Yilong Yang; Zhengshan Chen; Yingying Guo; Jinlong Zhang; Yaning Li; Xiaohong Song; Yi Chen; Lu Xia; Ling Fu; Lihua Hou; Junjie Xu; Changming Yu; Jianmin Li; Qiang Zhou; Wei Chen.
Afiliación
  • Xiangyang Chi; Beijing Institute of Biotechnology
  • Renhong Yan; Key Laboratory of Structural Biology of Zhejiang Province, Institute of Biology, Westlake Institute for Advanced Study, School of Life Sciences, Westlake Univer
  • Jun Zhang; Beijing Institute of Biotechnology
  • Guanying Zhang; Beijing Institute of Biotechnology
  • Yuanyuan Zhang; Key Laboratory of Structural Biology of Zhejiang Province, Institute of Biology, Westlake Institute for Advanced Study, School of Life Sciences, Westlake Univer
  • Meng Hao; Beijing Institute of Biotechnology
  • Zhe Zhang; Beijing Institute of Biotechnology
  • Pengfei Fan; Beijing Institute of Biotechnology
  • Yunzhu Dong; Beijing Institute of Biotechnology
  • Yilong Yang; Beijing Institute of Biotechnology
  • Zhengshan Chen; Beijing Institute of Biotechnology
  • Yingying Guo; Key Laboratory of Structural Biology of Zhejiang Province, Institute of Biology, Westlake Institute for Advanced Study, School of Life Sciences, Westlake Univer
  • Jinlong Zhang; Beijing Institute of Biotechnology
  • Yaning Li; Beijing Institute of Biotechnology
  • Xiaohong Song; Beijing Institute of Biotechnology
  • Yi Chen; Beijing Institute of Biotechnology
  • Lu Xia; Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University
  • Ling Fu; Beijing Institute of Biotechnology
  • Lihua Hou; Beijing Institute of Biotechnology
  • Junjie Xu; Beijing Institute of Biotechnology
  • Changming Yu; Beijing Institute of Biotechnology
  • Jianmin Li; Beijing Institute of Biotechnology
  • Qiang Zhou; Key Laboratory of Structural Biology of Zhejiang Province, Institute of Biology, Westlake Institute for Advanced Study, School of Life Sciences, Westlake Univer
  • Wei Chen; Beijing Institute of Biotechnology
Preprint en En | PREPRINT-BIORXIV | ID: ppbiorxiv-083964
ABSTRACT
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents a global public health threat. Most research on therapeutics against SARS-CoV-2 focused on the receptor binding domain (RBD) of the Spike (S) protein, whereas the vulnerable epitopes and functional mechanism of non-RBD regions are poorly understood. Here we isolated and characterized monoclonal antibodies (mAbs) derived from convalescent COVID-19 patients. An mAb targeting the N-terminal domain (NTD) of the SARS-CoV-2 S protein, named 4A8, exhibits high neutralization potency against both authentic and pseudotyped SARS-CoV-2, although it does not block the interaction between angiotensin-converting enzyme 2 (ACE2) receptor and S protein. The cryo-EM structure of the SARS-CoV-2 S protein in complex with 4A8 has been determined to an overall resolution of 3.1 Angstrom and local resolution of 3.4 Angstrom for the 4A8-NTD interface, revealing detailed interactions between the NTD and 4A8. Our functional and structural characterizations discover a new vulnerable epitope of the S protein and identify promising neutralizing mAbs as potential clinical therapy for COVID-19.
Licencia
cc_no
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Prognostic_studies Idioma: En Año: 2020 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Prognostic_studies Idioma: En Año: 2020 Tipo del documento: Preprint